RS Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

RS Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	$1.89M	Buy	24,250 +3,130	+15%	+$266K	0.02%	306
2016 Q1	$1.74M	Sell	21,120 -78,120	-79%	-$6.36M	0.02%	306
2015 Q4	$10.4M	Buy	99,240 +44,180	+80%	+$4.61M	0.09%	228
2015 Q3	$5.8M	Buy	55,060 +22,490	+69%	+$3M	0.05%	262
2015 Q2	$4.46M	Sell	32,570 -1,330	-4%	-$165K	0.04%	277
2015 Q1	$4.22M	Sell	33,900 -60,500	-64%	-$6.41M	0.04%	284
2014 Q4	$8.53M	Buy	+94,400	New	+$7.85M	0.08%	253
2013 Q4	–	Sell	-56,200	Closed	-$4.06M	–	331
2013 Q3	$4.06M	Sell	56,200 -308,370	-85%	-$20.5M	0.03%	257
2013 Q2	$20.3M	Buy	+364,570	New	+$22.7M	0.15%	161

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RS Investment Management's BMRN Position: Q2 2016 in Review

RS Investment Management increased its BioMarin Pharmaceuticals (BMRN) stake by 15% in Q2 2016, buying an estimated $266K and bringing the position to 24,250 shares worth $1.89M. The position accounts for 0.02% of the portfolio, ranked #306.

RS Investment Management first reported a position in BMRN in Q2 2013 and has held it in 9 quarters since. The position peaked at $20.3M in Q2 2013. 392 funds tracked by Wall St. Rank hold BMRN as of Q2 2016.

RS Investment Management held 24,250 shares of BioMarin Pharmaceuticals worth $1.89M as of Q2 2016.
RS Investment Management bought 3,130 BioMarin Pharmaceuticals shares in Q2 2016, an estimated $266K.
BioMarin Pharmaceuticals made up 0.02% of RS Investment Management's portfolio in Q2 2016, its #306 holding.
RS Investment Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 9 quarters since.
RS Investment Management's BioMarin Pharmaceuticals position peaked at $20.3M in Q2 2013.
392 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2016.

Based on RS Investment Management's 13F filing for Q2 2016, filed 26 Jul 2016.